Virunil 250

Description

Virunil 250 mg Infusion

Indications
Acyclovir intravenous infusion is indicated for the treatment of-
Acute clinical manifestations of Herpes simplex virus in immunocompromised patients
Severe primary or non-primary genital herpes in immune competent patients
Varicella zoster virus infection in immunocompromised patients
Herpes zoster (shingles) in immune competent patients who show very severe acute local or systemic manifestations of the disease
Herpes simplex encephalitis

Pharmacology
Acyclovir exerts its antiviral e­ects on Herpes simplex virus and Varicella zoster virus by interfering with DNA synthesis and inhibiting viral replication. In cells infected with Herpes virus, the antiviral activity of Acyclovir appears to depend principally on the intracellular conversion of the drug to Acyclovir Triphosphate. Acyclovir is converted to Acyclovir Monophosphate principally via virus coded thymidine kinase, the monophosphate is phosphorylated to diphosphate via cellular guanylate kinase and then via other cellular enzymes to the Triphosphate, which is the pharmacologically active form of the drug.

Dosage
Herpes simplex infection: For normal or immunocompromised immune status: 5 mg/kg every 8 hours
Very severe Herpes zoster infection (shingles): For normal immune status: 5 mg/kg every 8 hours
Varicella zoster infection: For immunocompromised immune status: 10 mg/kg every 8 hours
Herpes simplex encephalitis: For normal or immunocompromised immune status: 10 mg/kg every 8 hours
Each dose should be administered by slow intravenous infusion over a one-hour period.